Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787055 | 0.84 | PDPK1 (0.39) | RIPK1DYRK1APDPK1MAPK1 | |
| SCHEMBL4309792 | 0.78 | JAK3 (0.33) | — | |
| Pyrrole SCHEMBL12467466 | 0.76 | PDPK1 (0.38) | RIPK1PDPK1MAPK1 | |
| Carbamic Acid SCHEMBL1795160 | 0.69 | ACHE (0.35) | — | |
| SCHEMBL4102491 | 0.68 | KDM4E (0.48) | — | |
| Acetamide SCHEMBL4906100 | 0.67 | LMNA (0.38) | — | |
| SCHEMBL4112718 | 0.67 | P2RX7 (0.49) | DYRK1AMAPK1 | |
| SCHEMBL7052922 | 0.67 | KDM4E (0.32) | DYRK1A | |
| SCHEMBL10424836 | 0.65 | PDPK1 (0.38) | RIPK1PDPK1MAPK1 | |
| SCHEMBL19463620 | 0.64 | PIM1 (0.43) | RIPK1PDPK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136570-A1 | Taste-Masked Tablets and Granules | UNIVERSITAT ZURICH (CH) | 2009-05-28 | — | — | US | disclosed |
| EP-1904067-A2 | PHARMACEUTICAL FORMULATION OF CARBOXAMIDE HIV INTEGRASE INHIBITORS CONTAINING A RELEASE RATE CONTROLLING COMPOSITION | Merck & Co., Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007087188-A2 | TASTE-MASKED TABLETS AND GRANULES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006060711-A2 | PHARMACEUTICAL FORMULATION OF CARBOXAMIDE HIV INTEGRASE INHIBITORS CONTAINING A RELEASE RATE CONTROLLING COMPOSITION | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136570-A1 | Taste-Masked Tablets and Granules | TAS2R30, TAS2R40, TAS2R42 | RIPK1 300/4885DYRK1A 3371/4885PDPK1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.